Global Drugs of UDCA Market Size By Type (Capsule, Tablet), By Application (Gallstone, Hepatopathy), By Region, And Segment Forecasts, 2023 to 2032

The Global Drugs of UDCA (Ursodeoxycholic Acid) Market was valued at USD 745 million in 2023 and is projected to reach USD 1.28 billion by 2031, expanding at a CAGR of 7.1% during the forecast period of 2023–2031. UDCA drugs are primarily used for the treatment of primary biliary cholangitis, gallstone dissolution, and other hepatobiliary disorders. The rising prevalence of liver-related conditions, increasing awareness about liver health, and expanded clinical indications are key drivers fueling the growth of this market.

Drivers:

1. Rising Prevalence of Hepatic and Biliary Disorders:

Growing global incidence of chronic liver diseases, including cholestatic conditions and gallbladder disorders, is significantly boosting the demand for UDCA drugs. Primary biliary cholangitis (PBC), a rare autoimmune liver disease, continues to be a major therapeutic area for UDCA.

2. Increasing Geriatric Population:

The aging population, particularly in developed regions, is more prone to gallstones and liver dysfunctions, thereby contributing to the growing consumption of UDCA formulations.

3. Expanded Therapeutic Applications:

Emerging research indicates the potential of UDCA in treating various conditions beyond traditional indications, including non-alcoholic steatohepatitis (NASH) and certain neurodegenerative disorders, creating new opportunities for market growth.

Restraints:

1. Availability of Alternative Treatments:

The availability of alternative therapies such as obeticholic acid and newer bile acid analogs could hamper UDCA drug sales in certain patient segments.

2. Regulatory Challenges:

Strict regulatory pathways and the need for extensive clinical trials for new indications or formulations may delay product approvals, limiting faster market penetration.

Opportunity:

1. Rising Healthcare Access in Emerging Markets:

Countries in Asia-Pacific, Latin America, and the Middle East are experiencing growing healthcare infrastructure and awareness about liver diseases, presenting significant market potential for UDCA drug manufacturers.

2. Development of Novel Formulations:

Research efforts are underway to develop extended-release, combination, or pediatric-friendly UDCA drugs, aimed at enhancing patient compliance and expanding its application base.

Market by System Type Insights:

Based on formulation type, Tablet and Capsule segments dominate the market, with tablets being the largest revenue contributor in 2023. Tablets are widely preferred due to ease of administration and dosing accuracy. However, Liquid Oral Suspensions are gaining momentum, especially in pediatric and geriatric applications, and are expected to witness the fastest growth rate during the forecast period.

Market by End-use Insights:

Hospital Pharmacies led the market in 2023, accounting for the majority of UDCA drug sales, attributed to direct physician prescriptions and treatment of inpatients with hepatobiliary conditions. Retail Pharmacies and Online Pharmacies are also growing segments, fueled by the increasing trend of at-home medication management and e-pharmacy platforms.

Market by Regional Insights:

North America dominated the market in 2023 due to high awareness of liver diseases, established healthcare infrastructure, and significant adoption of prescription-based therapies. However, the Asia-Pacific region is expected to experience the fastest growth, driven by increasing diagnosis rates, rising income levels, and growing government initiatives toward liver disease screening and treatment.

Competitive Scenario:

Key players in the Global Drugs of UDCA Market include Zydus Lifesciences, Dr. Reddy’s Laboratories, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Eisai Co., Ltd., Lannett Company, Glenmark Pharmaceuticals, and Lupin Limited. These companies are actively involved in expanding their UDCA product lines through regulatory approvals, regional expansions, and strategic collaborations.

Recent Developments:

In 2024, Eisai Co., Ltd. launched a next-generation UDCA formulation for patients with primary biliary cholangitis in Japan.

In 2023, Dr. Reddy’s Laboratories received USFDA approval for its generic UDCA tablets targeting the U.S. market.

In 2022, Sun Pharmaceutical Industries expanded its liver care product portfolio across Southeast Asia, including UDCA-based formulations.

Scope of Work – Global Drugs of UDCA Market

Key Market Developments:

2024: Eisai Co., Ltd. unveiled a modified-release UDCA capsule to improve dosage convenience in elderly patients.

2023: Glenmark Pharmaceuticals announced a licensing agreement for UDCA distribution in Brazil and Mexico.

2022: Zydus Lifesciences launched its UDCA line in Eastern Europe as part of its liver health initiative.

FAQs:

1. What is the current market size of the Global Drugs of UDCA Market?

The market was valued at USD 745 million in 2023.

2. What is the major growth driver of the Global Drugs of UDCA Market?

The primary driver is the rising prevalence of liver and gallbladder disorders globally.

3. Which is the largest region during the forecast period in the Global Drugs of UDCA Market?

North America currently leads, but Asia-Pacific is expected to witness the fastest growth.

4. Which segment accounted for the largest market share in the Global Drugs of UDCA Market?

The tablet formulation segment held the largest share in 2023.

5. Who are the key market players in the Global Drugs of UDCA Market?

Major players include Zydus Lifesciences, Dr. Reddy’s, Sun Pharma, Teva, Eisai, and Glenmark.